Taken together, ITGA1/ITGA2/TEAD1 expression level in the PCa specimens could be considered as novel additional biomarkers helping to make more accurate treatment decisions in the clinic for PCa patients with high PSA levels and intermediate Gleason score 7. The gene discussed is ITGA2; the disease is posterior cortical atrophy.